Clinical Trial Update: Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating cryoablation in combination with tislelizumab and lenvatinib as second-line or later therapy for advanced hepatocellular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING